Innovative Oncology Focus 858 Therapeutics specializes in developing small molecule drugs targeting novel therapeutic areas in oncology, especially for cancers resistant to existing treatments, indicating potential for partnerships in advanced cancer drug development and clinical trials.

Recent Funding Success With a recent $50 million Series B financing, the company demonstrates strong investor confidence, providing opportunities for strategic collaborations, joint ventures, or co-development projects to accelerate their drug pipeline.

Expansion through Acquisition The acquisition of Gotham Group, an RNA-focused biotech, broadens 858's technological capabilities and portfolio, creating prospects for sales of research tools, partnerships in RNA therapeutics, or licensing opportunities.

Strategic Location Headquartered in San Diego with operations in New York City, 858 is well-positioned to access leading academic institutions, scientific talent, and biotech innovation hubs, facilitating collaborations and outsourcing opportunities.

Focus on Cutting-edge Technologies Utilizing advanced research areas such as epigenetics, single cell genomics, and innate immunity, 858 offers opportunities to provide specialized laboratory services, research tools, or technology licensing to enhance their drug discovery process.